Literature DB >> 7720101

The molecular biology of the flavin-containing monooxygenases of man.

I R Phillips1, C T Dolphin, P Clair, M R Hadley, A J Hutt, R R McCombie, R L Smith, E A Shephard.   

Abstract

cDNA clones encoding five distinct members of the FMO family of man (FMOs 1, 2, 3, 4 and 5) were isolated by a combination of library screening and reverse transcription-polymerase chain reaction techniques. The deduced amino acid sequences of the human FMOs have 82-87% identity with their known orthologues in other mammal but only 51-57% similarity to each other. The hydropathy profiles of the proteins are very similar. From the calculated rate of evolution of FMOs (a 1% change in sequence per 6 million years) it would appear that individual members of the FMO gene family arose by duplication of a common ancestral gene some 250-300 million years ago. Each of the FMO genes was mapped by the polymerase chain reaction to the long arm of human chromosome 1. The localization of the FMO1 gene was further refined to 1q23-q25 by in situ hybridization of human metaphase chromosomes. RNase protection assays demonstrated that in man each FMO gene displays a distinct developmental and tissue-specific pattern of expression. In the adult, FMO1 is expressed in kidney but not in liver, whereas in the foetus its mRNA is abundant in both organs. FMO3 expression is essentially restricted to the liver in the adult and the mRNA is either absent, or present in low amounts, in foetal tissues. FMO4 is expressed more constitutively. Human FMO1 and FMO3 cDNAs were functionally expressed in prokaryotic and eukaryotic cells. FMO1 and FMO3, expressed in either system, displayed product stereoselectivity in their catalysis of the N-oxidation of the pro-chiral tertiary amines, N-ethyl-N-methylaniline (EMA) and pargyline. Both enzymes were stereoselective with respect to the production of the (-)-S-enantiomer of EMA N-oxide. But in the case of pargyline, the enzymes displayed opposite stereoselectivity, FMO1 producing solely the (+)-enantiomer and FMO3 predominantly the (-)-enantiomer of the N-oxide.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720101     DOI: 10.1016/0009-2797(94)03580-2

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  22 in total

1.  Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population.

Authors:  Makiko Shimizu; Charles K Allerston; Elizabeth A Shephard; Hiroshi Yamazaki; Ian R Phillips
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

Review 2.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

Review 3.  Flavin-containing monooxygenases in aging and disease: Emerging roles for ancient enzymes.

Authors:  Ryan Rossner; Matt Kaeberlein; Scott F Leiser
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

Review 4.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

5.  Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity.

Authors:  E Störmer; I Roots; J Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

6.  Chlorogenic acid prevents acetaminophen-induced liver injury: the involvement of CYP450 metabolic enzymes and some antioxidant signals.

Authors:  Chun Pang; Yu-chen Sheng; Ping Jiang; Hai Wei; Li-li Ji
Journal:  J Zhejiang Univ Sci B       Date:  2015-07       Impact factor: 3.066

7.  The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa.

Authors:  Krishna R Veeramah; Mark G Thomas; Michael E Weale; David Zeitlyn; Ayele Tarekegn; Endashaw Bekele; Nancy R Mendell; Elizabeth A Shephard; Neil Bradman; Ian R Phillips
Journal:  Pharmacogenet Genomics       Date:  2008-10       Impact factor: 2.089

8.  Human flavin-containing monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide.

Authors:  Asvi A Francois; Clinton R Nishida; Paul R Ortiz de Montellano; Ian R Phillips; Elizabeth A Shephard
Journal:  Drug Metab Dispos       Date:  2008-10-23       Impact factor: 3.922

Review 9.  Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives.

Authors:  Irfan M Hisamuddin; Vincent W Yang
Journal:  Pharmacogenomics       Date:  2007-06       Impact factor: 2.533

10.  Alternative promoters and repetitive DNA elements define the species-dependent tissue-specific expression of the FMO1 genes of human and mouse.

Authors:  Elizabeth A Shephard; Pritpal Chandan; Milena Stevanovic-Walker; Mina Edwards; Ian R Phillips
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.